Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113


The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17.


Novel paradigms in systemic lupus erythematosus.

Dörner T, Furie R.

Lancet. 2019 Jun 8;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-X. Epub 2019 Jun 6. Review.


Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.

BMJ Open. 2019 Mar 20;9(3):e025687. doi: 10.1136/bmjopen-2018-025687.


Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.

Arthritis Rheumatol. 2019 Feb 16. doi: 10.1002/art.40861. [Epub ahead of print]


Baricitinib for systemic lupus erythematosus - Authors' reply.

Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW.

Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. No abstract available.


Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N.

J Clin Invest. 2019 Mar 1;129(3):1359-1371. doi: 10.1172/JCI124466. Epub 2019 Feb 18.


Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL.

Semin Arthritis Rheum. 2018 Dec 4. pii: S0049-0172(18)30493-1. doi: 10.1016/j.semarthrit.2018.11.005. [Epub ahead of print]


Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.

van Vollenhoven RF, Stohl W, Furie RA, Fox NL, Groark JG, Bass D, Kurtinecz M, Pobiner BF, Eastman WJ, Gonzalez-Rivera T, Gordon D.

Lupus Sci Med. 2018 Nov 26;5(1):e000288. doi: 10.1136/lupus-2018-000288. eCollection 2018.


Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.

Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, Illei G, Tummala R.

Lupus Sci Med. 2018 Nov 26;5(1):e000284. doi: 10.1136/lupus-2018-000284. eCollection 2018.


Inflammatory arthritis: a unique presentation of human anaplasmosis.

El Khoury L, Furie R.

Clin Rheumatol. 2019 Jan;38(1):257-259. doi: 10.1007/s10067-018-4395-5. Epub 2018 Dec 11. Review.


Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.

Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne-Steele M, Pan W, Yang Q, Han J, Lesser M, Rothstein TL, Furie R, Mackay M, Aranow C, Davidson A.

JCI Insight. 2018 Sep 6;3(17). pii: 122525. doi: 10.1172/jci.insight.122525. eCollection 2018 Sep 6.


Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW.

Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Erratum in: Lancet. 2018 Aug 11;392(10146):476.


Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie RA, Dervieux T.

Lupus Sci Med. 2018 May 23;5(1):e000263. doi: 10.1136/lupus-2018-000263. eCollection 2018.


Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.

Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG.

Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12.


Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.

Furie R, Wang L, Illei G, Drappa J.

Lupus. 2018 May;27(6):955-962. doi: 10.1177/0961203318758506. Epub 2018 Feb 20.


Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS.

World J Gastrointest Pharmacol Ther. 2018 Feb 6;9(1):8-13. doi: 10.4292/wjgpt.v9.i1.8.


Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.

Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25.


Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature.

Anderson E, Shah B, Davidson A, Furie R.

Semin Arthritis Rheum. 2018 Aug;48(1):90-104. doi: 10.1016/j.semarthrit.2017.12.004. Epub 2017 Dec 8. Review.


Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.

Furie RA, Mitrane M, Zhao E, Becker PM.

Lupus Sci Med. 2017 Dec 27;4(1):e000240. doi: 10.1136/lupus-2017-000240. eCollection 2017.


Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus.

Presto JK, Okon LG, Feng R, Wallace DJ, Furie R, Fiorentino D, Werth VP.

Br J Dermatol. 2018 Jun;178(6):1308-1314. doi: 10.1111/bjd.16337. Epub 2018 Apr 17.


Systemic lupus erythematosus.

Furie R, Cervera R.

Best Pract Res Clin Rheumatol. 2017 Jun;31(3):289-290. doi: 10.1016/j.berh.2017.10.005. Epub 2017 Nov 2. No abstract available.


Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, Petri M, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD.

Rheumatology (Oxford). 2018 Jan 1;57(1):125-133. doi: 10.1093/rheumatology/kex368.


Antiphospholipid Syndrome: It's Far More Than You Think.

Annem C, Furie RA.

J Clin Rheumatol. 2017 Aug;23(5):278-284. doi: 10.1097/RHU.0000000000000564. No abstract available.


Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S; CD1013 Study Investigators.

Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962.


Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Buyon J, Furie R, Putterman C, Ramsey-Goldman R, Kalunian K, Barken D, Conklin J, Dervieux T.

Lupus Sci Med. 2016 Sep 30;3(1):e000165. eCollection 2016.


B cells from African American lupus patients exhibit an activated phenotype.

Menard LC, Habte S, Gonsiorek W, Lee D, Banas D, Holloway DA, Manjarrez-Orduno N, Cunningham M, Stetsko D, Casano F, Kansal S, Davis PM, Carman J, Zhang CK, Abidi F, Furie R, Nadler SG, Suchard SJ.

JCI Insight. 2016 Jun 16;1(9):e87310. doi: 10.1172/jci.insight.87310.


Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group.

Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856.


T-cell-directed therapies in systemic lupus erythematosus.

Nandkumar P, Furie R.

Lupus. 2016 Sep;25(10):1080-5. doi: 10.1177/0961203316652493. Review.


Update on clinical trials in systemic lupus erythematosus.

Narain S, Furie R.

Curr Opin Rheumatol. 2016 Sep;28(5):477-87. doi: 10.1097/BOR.0000000000000311. Review.


Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W; CD1067 study investigators.

Ann Rheum Dis. 2016 Nov;75(11):1909-1916. doi: 10.1136/annrheumdis-2015-208562. Epub 2016 Mar 23.


Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.

Furie R, Toder K, Zapantis E.

Semin Nephrol. 2015 Sep;35(5):509-20. doi: 10.1016/j.semnephrol.2015.08.012. Review.



Pope JE, Rothfield NF, Ramsey-Goldman R, Douglas Smith C, Bernatsky SR, Furie RA, Hudson M, Burgos-Vargas R, Senécal JL, Inanç M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1053-4. doi: 10.1002/acr.22777. No abstract available.


Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO 3rd, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL Jr, Gregersen PK, Niewold TB.

Ann Rheum Dis. 2016 Oct;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001. Epub 2015 Nov 6.


Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.

Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, Starr AJ, Imundo LF, Buyon J, Furie RA, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, van Vollenhoven RF, Wallace DJ, Askanase A.

J Rheumatol. 2015 Dec;42(12):2288-95. doi: 10.3899/jrheum.150470. Epub 2015 Nov 1.


Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.

Wallace DJ, Hobbs K, Clowse ME, Petri M, Strand V, Pike M, Merrill JT, Leszczyński P, Neuwelt CM, Jeka S, Houssiau F, Keiserman M, Ordi-Ros J, Bongardt S, Kilgallen B, Galateanu C, Kalunian K, Furie R, Gordon C.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):534-43. doi: 10.1002/acr.22694.


Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.

Ann Rheum Dis. 2016 Feb;75(2):332-40. doi: 10.1136/annrheumdis-2015-207654. Epub 2015 Aug 20.


Treatment Algorithms in Systemic Lupus Erythematosus.

Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE.

Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237-45. doi: 10.1002/acr.22589.


Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T.

Lupus Sci Med. 2014 Oct 1;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014.


Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.

Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014.


Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B.

Blood. 2014 Jul 24;124(4):611-22. doi: 10.1182/blood-2014-02-554980. Epub 2014 May 13.


A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study.

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19.


Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.

Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT.

Arthritis Rheumatol. 2014 Feb;66(2):379-89. doi: 10.1002/art.38260.


Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.


Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.


Targeting the complement system in systemic lupus erythematosus and other diseases.

Barilla-Labarca ML, Toder K, Furie R.

Clin Immunol. 2013 Sep;148(3):313-21. doi: 10.1016/j.clim.2013.02.014. Epub 2013 Mar 5. Review.


Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.

Mosak J, Furie R.

Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575. Review.


Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups.

Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4.


Comparative safety of therapies in systemic lupus erythematosus.

Mosak J, Furie R.

Rheum Dis Clin North Am. 2012 Nov;38(4):795-807. doi: 10.1016/j.rdc.2012.08.009. Review.


Supplemental Content

Support Center